Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
123 hedge funds and large institutions have $1.21B invested in Alder Biopharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 52 increasing their positions, 27 reducing their positions, and 21 closing their positions.
101% more call options, than puts
Call options by funds: $750K | Put options by funds: $373K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
93% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 27
64% more capital invested
Capital invested by funds: $733M → $1.21B (+$473M)
1% less funds holding
Funds holding: 124 → 123 (-1)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$69.9M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$29.9M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$22.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.1M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCIM
TIAA CREF Investment Management
New York
|
-$8.35M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$7.71M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.62M |
| 4 |
Citigroup
New York
|
-$4.07M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.24M |
ALDR Hedge Fund Activity: Q1 2019 in Review
123 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q1 2019, worth a combined $1.21B — up 64% from $733M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ALDR and 20 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 52 added.
The largest buyer was Wellington Management Group, adding an estimated $69.9M. The largest seller was TIAA CREF Investment Management, cutting an estimated $8.35M.
- 123 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q1 2019, down from 124 in Q4 2018.
- Funds reported $1.21B of Alder Biopharmaceuticals stock for Q1 2019, up 64% quarter-over-quarter.
- 20 funds opened new Alder Biopharmaceuticals positions in Q1 2019 and 21 closed out, a net change of -1 holder.
- The largest Alder Biopharmaceuticals buyer in Q1 2019 was Wellington Management Group, an estimated $69.9M added.
- The largest Alder Biopharmaceuticals seller in Q1 2019 was TIAA CREF Investment Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q1 2019.